Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Civica Rx aims to supply drugs that are unavailable. Photo: George Frey/ Getty Images.
The nonprofit drug supplier Civica Rx, which aims to supply drugs that are unavailable due to shortage or price, will also try to force transparency about how money flows through the hands of middlemen.
What they're saying: "We will not pay listing fees or rebates to anybody in the middle of the process," CEO Martin VanTrieste said in a briefing on Thursday.
- If a hospital wants to use, for example, its local wholesaler, Civica Rx will make it clear how much it's charging the wholesaler so that the hospital can know how much the wholesaler is keeping.
- The hospital can then make a decision about whether they think the middlemen's services are worth the price tag.
Why it matters: This information isn't available for most drugs, and we don't know how much of a drug's price is absorbed by the supply chain. This model could help answer that question.
Go deeper: Trump administration proposes rolling back drug rebates.